Michael Yee (Allogene open house Credit: Jeff Rumans)
February 28, 2022 10:29 AM EST
Cell/Gene Tx
FDA+

Hold the phone, bio­phar­ma: FDA-im­posed clin­i­cal holds are on the rise

Max Gelman

Senior Editor

Are clin­i­cal holds on the rise? Ac­cord­ing to one analy­sis, signs point to yes, and one field, in par­tic­u­lar, is prov­ing a like­ly cul­prit. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times